Qsymia is a prescription weight management medication that combines two separate active ingredients in one extended release capsule: phentermine and topiramate. Employers and employees who see a positive screen sometimes ask whether the medication itself is the cause, and whether a prescription for Qsymia should be disclosed before a workplace drug test. The short answer is that the phentermine component can produce a presumptive positive on an amphetamine immunoassay panel, while the topiramate component is not a controlled substance and is not an analyte that standard workplace panels look for at all. What happens next depends on confirmation testing and the medical review officer process, not on the screening device alone.
What is actually inside Qsymia
According to the product labeling on file with the National Library of Medicine, Qsymia's DailyMed listing describes it as phentermine combined with topiramate in an extended release capsule, intended for chronic weight management alongside diet and physical activity. Phentermine is a sympathomimetic amine that is structurally related to amphetamine, which is exactly why it can interact with an amphetamine class immunoassay. Topiramate is an anticonvulsant with a completely different chemical structure and mechanism, and it has no cross reactivity with amphetamine class assays.
Phentermine, the DEA schedule, and the amphetamine screen
Phentermine is listed as a Schedule IV controlled substance in the DEA's current list of controlled substances, reflecting a lower abuse potential than amphetamine or methamphetamine, which sit in Schedule II. That lower schedule does not change how an immunoassay screen behaves. Rapid amphetamine strips and dip cards, along with cup based panels that include an AMP line, use antibodies tuned to the amphetamine class as a whole. Because phentermine shares a core structure with amphetamine, it can bind those antibodies closely enough to push a sample over the screening cutoff and return a presumptive positive, even though no amphetamine or methamphetamine is actually present. This is the same cross reactivity pattern documented for several other prescription stimulants and appetite suppressants; for background on how it plays out for the phentermine molecule specifically, see our phentermine employer guide.
Employers that run pre employment or random programs on a panel that includes amphetamine should expect this possibility whenever a current prescription for phentermine or a phentermine combination product like Qsymia is in the employee's history. Programs built on an amphetamine inclusive 5 panel screen or a broader 10 panel drug test will see the AMP line react the same way regardless of how many other drug classes the panel covers.
What topiramate does and does not do
Topiramate is not scheduled by the DEA and is not targeted by any standard rapid immunoassay panel sold for workplace, probation, or clinical use. It will not produce a line change on an amphetamine strip, an opiate strip, or any other standard drug class line, and it is not something a lab is screening for unless a specific anticonvulsant blood or serum test has been ordered for a clinical reason unrelated to workplace drug testing. We cover the topiramate half of this combination in more detail in our topiramate and workplace panels post. For a Qsymia user, topiramate is simply not part of the drug test conversation.
Screening versus confirmation: why a presumptive positive is not the final word
A rapid dip card, cassette, or cup reader is an initial screen. It is built for speed and broad class detection, not for naming an exact compound. When an amphetamine line reacts, a compliant program sends the specimen, or in some settings a split portion of it, on to laboratory confirmation using gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry. These methods separate and identify the specific molecule present rather than reacting to a chemical family. Because phentermine is not amphetamine or methamphetamine at the molecular level, a specimen that screened presumptive positive purely because of phentermine will typically confirm negative for amphetamine and negative for methamphetamine once the lab runs the targeted confirmatory method. Programs that rely on point of care results without a confirmation step for safety sensitive decisions are taking on legal and operational risk that most employer policies are written to avoid.
Any lab that runs this kind of confirmation should be asked directly which specific amphetamine class analytes its confirmatory method targets, since panel coverage and confirmation menus vary by laboratory. Facilities building out a full screen to confirmation workflow often pair a multi panel drug test cup for the initial collection with a contracted reference lab for confirmation on anything that screens positive.
The employer and MRO process for a confirmed result
When a laboratory reports a confirmed amphetamine class positive back to a medical review officer, the MRO's job is to contact the employee, review current prescriptions, and determine whether a legitimate medical explanation accounts for the result before it is reported to the employer. An employee taking Qsymia should be ready to show the prescription and the pharmacy label if asked, since that documentation is the fastest way for an MRO to close out the review. If the confirmatory test comes back negative for amphetamine and methamphetamine, as is typical when phentermine alone caused the screening reaction, the MRO generally reports the test negative overall, because the confirmed analyte was never actually present. If a confirmatory test did somehow return a true amphetamine or methamphetamine finding alongside a phentermine prescription, that is a separate medical review conversation that has nothing to do with the phentermine itself. Employers should never assume a specific outcome and should let the MRO process, not the initial screen, drive any employment decision.
Depending on internal policy, an employer may still document that an employee disclosed a phentermine or phentermine combination prescription, separate from the drug test result itself, if the role involves safety sensitive duties where sedation, appetite suppression, or stimulant like side effects could matter. That is a fitness for duty and job safety conversation for the employer and, where applicable, the employee's own prescribing clinician, not a drug test compliance issue.
Does DOT testing treat Qsymia differently
Phentermine is not one of the specific drug classes that a DOT regulated test is built to detect. The DOT panel, run under 49 CFR Part 40, targets amphetamines, cocaine metabolite, marijuana metabolite, opioids, and phencyclidine, using HHS certified laboratories and HHS set cutoff concentrations for the screen and the confirmatory test. Those same HHS certified laboratories and federal workplace testing standards, administered through the SAMHSA workplace programs division, are also the backbone that most non-DOT employer programs model their own cutoffs and confirmation rules on. Phentermine is not itself one of the named target analytes, but because it shares the amphetamine core structure it can still trigger the amphetamines screening cutoff on a DOT specimen, which then goes to confirmation like any other DOT screen. An MRO working a DOT case follows the same documentation review described above, and a phentermine only reaction that does not confirm as amphetamine or methamphetamine under Part 40's procedures is reported negative. Separately, a DOT medical examiner performing the physical qualification exam may still ask about any medication, including phentermine or a phentermine combination product, as part of a fitness for duty conversation, since that review is independent of the drug test result and is not something this article can resolve generically. DOT questions always vary by mode and by the specific medical examiner, so carriers should confirm specifics with their own compliance resource rather than relying on a drug test blog post.
| Component | DEA schedule | Reacts on a standard amphetamine screen | Confirms as amphetamine or methamphetamine |
|---|---|---|---|
| Phentermine | Schedule IV | Can trigger a presumptive positive | No, it is a different molecule |
| Topiramate | Not scheduled | No reaction on any standard panel line | Not applicable |
Building a compliant program around prescription stimulant lookalikes
Employers who see this pattern often enough to want a formal process typically standardize three things: a panel that reliably flags the amphetamine class in the first place, a standing arrangement with a laboratory for GC-MS or LC-MS confirmation on every non-negative screen, and a documented prescription verification step with an MRO before any adverse action. For the collection itself, programs commonly use a urine dip card for quick screening at the site, or a saliva based oral fluid test where observed urine collection is not practical, and send anything presumptive positive out through a reference laboratory confirmation service before it ever reaches a hiring manager or supervisor. None of this changes because the prescription on file happens to be Qsymia rather than phentermine alone; the screen to confirm to MRO workflow is the same regardless of which phentermine containing product an employee is taking.
Frequently asked questions
Does Qsymia show up as amphetamine on a drug test?
The phentermine portion of Qsymia can cause a presumptive positive on an amphetamine immunoassay screen because phentermine shares a core structure with amphetamine. The topiramate portion does not react on any standard panel.
Why does phentermine cause a presumptive positive on an amphetamine screen?
Immunoassay screens use antibodies that respond to the amphetamine chemical class broadly rather than to one exact molecule, so a structurally related compound like phentermine can bind closely enough to cross the screening cutoff.
Will Qsymia cause a confirmed positive amphetamine result?
Typically no. Laboratory confirmation by GC-MS or LC-MS identifies the specific molecule present, and because phentermine is not amphetamine or methamphetamine, a screen that reacted only because of phentermine generally confirms negative for those analytes.
Does topiramate show up on a drug test?
No. Topiramate is not a controlled substance and is not an analyte that standard rapid panels or standard laboratory drug test confirmation menus look for.
Is phentermine on the DOT drug test panel?
Phentermine is not one of the five specific drug classes targeted under 49 CFR Part 40, but because it can trigger the amphetamines screening cutoff it may still prompt a confirmatory test, which generally resolves as negative for amphetamine and methamphetamine when phentermine is the only cause.
What should an employee taking Qsymia do before a drug test?
Bring the prescription and pharmacy label so it is available if the medical review officer calls to review a non-negative screen. The MRO process, not the initial screen, determines the final reported result.
This article is general information for employers and employees about drug test science and process. It is not legal advice and not medical advice, and it does not replace guidance from a medical review officer, a compliance attorney, or a prescribing clinician.
